Regeneron Third-Quarter Revenue Climbs 36% to $5.12 Billion
Regeneron said third-quarter revenue rose on record sales for three drugs, led by Dupixent. Analysts polled by FactSet expected revenue of $4.56 billion.
By Kelly CloonanRegeneron Pharmaceuticals' quarterly revenue grew on record sales for a trio of drugs.The drugmaker said Friday third-quarter revenue climbed 36% to $5.12 billion. Analysts polled by FactSet expected $4.56 billion.The growth was boosted by higher sales of Dupixent, which is approved…